EudraVigilance
On November 22, 2017, the European Medicines Agency (EMA) rolled out a new version of EudraVigilance, the European-wide platform for managing suspected adverse drug reaction (ADR) reports within the European Economic Area (EEA).
The aim of this significant update was to streamline the submission and analysis of suspected adverse reactions, thereby enhancing medicinal product surveillance and increasing the efficiency of the reporting process for all stakeholders.
This implementation resulted in several key changes to adverse reaction reporting management, including:
- The mandatory reporting of adverse reactions directly to EudraVigilance by Marketing Authorization (MA) Holders;
- The adaptation of the Italian National Pharmacovigilance Network (RNF) to ensure compatibility with the European-level system;
- The introduction of a re-routing system, enabling seamless data flow between Competent Authorities and EudraVigilance to ensure the integrity and completeness of both national and European databases.
Di Renzo Regulatory Affairs operates a specialized pharmacovigilance unit, featuring experts who specialize in the daily screening of EudraVigilance adverse reaction reports and comprehensive case management.